New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe.

ABSTRACT: In recent years, treatment options for patients with advanced biliary tract cancer (BTC) have increased significantly due to the positive results from phase 2/3 clinical trials of immune checkpoint inhibitors, combined with chemotherapy, and molecularly targeted agents. These advances have led to the need for molecular testing to identify actionable alterations and patients amenable to targeted therapies. However, these improvements have brought with them many questions and challenges, including the identification of resistance mechanisms and therapeutic sequences. In this Series paper we aim to provide an overview of the current systemic treatment options for patients with BTC, highlighting disparities in access to innovative treatments and molecular testing across European countries, whi

SUBMITTER: Rimassa L 

PROVIDER: S-EPMC11910789 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature